907 results on '"Milano, Filippo"'
Search Results
2. Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies
3. Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia
4. Combining distribution modelling and phylogeography to understand present, past and future of an endangered spider
5. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target
6. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
7. Old but not obsolete: Dimensional analysis in nondestructive testing and evaluation
8. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
9. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
10. Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia: Outcomes and Prognostic Factors
11. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.
12. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
13. Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
14. Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients
15. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
16. Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML
17. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels
18. Second Allogeneic Hematopoietic Cell Transplantation for Relapse in Adults with Acute Myeloid Leukemia: Outcomes and Prognostic Factors
19. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy
20. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
21. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy
22. Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
23. Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
24. T-Cell Large Granular Lymphocyte Population Involving Chimeric Antigen Receptor-Modified T (CAR T) Cells in Patients with Cytopenia after CD19-Targeted CAR T-Cell Therapy: Case Series
25. BLE-Based Indoor Localization: Analysis of Some Solutions for Performance Improvement
26. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
27. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients
28. Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation
29. Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia
30. Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience
31. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
32. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
33. Cord blood maternal microchimerism following unrelated cord blood transplantation
34. Guidelines for Cord Blood Unit Selection
35. Guidelines for Cord Blood Unit Thaw and Infusion
36. Application of dimensional analysis to ECT in the era of NDE 4.0.
37. Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study
38. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
39. Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation
40. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting
41. Factors associated with long-term outcomes of CD19 chimeric antigen receptor T-cell therapy for relapsedrefractory chronic lymphocytic leukemia 6-year follow-up
42. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel
43. Timing of Anti-PD-L1 Antibody Initiation Affects Efficacy/Toxicity of CD19 CAR-T Cell Therapy for Large B-Cell Lymphoma
44. Forensic analysis of planned and unplanned complex suicides: a case series
45. Taxonomy, ecology and conservation of the cave-dwelling spider Histopona palaeolithica , with the description of H. petrovi sp. nov. (Araneae: Agelenidae)
46. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
47. Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications
48. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources
49. A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients
50. P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.